Basic Information
| RNALocate ID: | RLID:11001714 |
| RNA Symbol: | hsa-miR-124-3p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-124-3p |
| RNA ID: | miRBase:MIMAT0000422 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 24797360 |
| Tissue/Cell Line: | Cerebrospinal fluid |
| Method: | RNA sequencing |
| Description: | Differentially expressed miRNAs detected in the cerebrospinal fluid (CSF). Data are collected from Table 1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001752 | Mitochondrion | Cell line (HEK-293) | 22984580 |
| RLID:11001713 | Exosome | Plasma | 23663360 |
| RLID-D:11000075 | Exosome | Blood | |
| RLID-D:11000350 | Microvesicle | Blood|Fibroblasts|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-124-3p | Inflammatory bowel disease | MNDR-E-MI-06103 |
| MNDR | hsa-miR-124-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-06104 |
| MNDR | hsa-miR-124-3p | Oral squamous cell carcinoma | MNDR-E-MI-06105 |
| MNDR | hsa-miR-124-3p | Medulloblastoma | MNDR-E-MI-06106 |
| MNDR | hsa-miR-124-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-06107 |
| MNDR | hsa-miR-124-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-06108 |
| MNDR | hsa-miR-124-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-06109 |
| MNDR | hsa-miR-124-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-06110 |
| MNDR | hsa-miR-124-3p | Her2-receptor positive breast cancer | MNDR-E-MI-06111 |
| MNDR | hsa-miR-124-3p | Anencephaly | MNDR-E-MI-06112 |
| MNDR | hsa-miR-124-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-06113 |
| MNDR | hsa-miR-124-3p | Lupus nephritis | MNDR-E-MI-06114 |
| MNDR | hsa-miR-124-3p | Prostate cancer | MNDR-E-MI-06115 |
| MNDR | hsa-miR-124-3p | Chronic lymphocytic leukemia | MNDR-E-MI-06116 |
| MNDR | hsa-miR-124-3p | Gastric cancer | MNDR-E-MI-06117 |
| MNDR | hsa-miR-124-3p | Alzheimer disease | MNDR-E-MI-06118 |
| MNDR | hsa-miR-124-3p | Bladder cancer | MNDR-E-MI-06119 |
| MNDR | hsa-miR-124-3p | Dysautonomia familial | MNDR-E-MI-06120 |
| MNDR | hsa-miR-124-3p | Seizures | MNDR-E-MI-06121 |
| MNDR | hsa-miR-124-3p | Friedreich ataxia | MNDR-E-MI-06122 |
| MNDR | hsa-miR-124-3p | Huntington disease | MNDR-E-MI-06123 |
| MNDR | hsa-miR-124-3p | Chorea | MNDR-E-MI-06124 |
| MNDR | hsa-miR-124-3p | Cardiovascular disease | MNDR-E-MI-06125 |
| MNDR | hsa-miR-124-3p | Brain cancer | MNDR-E-MI-06126 |
| MNDR | hsa-miR-124-3p | Lung cancer | MNDR-E-MI-06127 |
| MNDR | hsa-miR-124-3p | Fragile x syndrome | MNDR-E-MI-06128 |
| MNDR | hsa-miR-124-3p | Parkinson disease | MNDR-E-MI-06129 |
| MNDR | hsa-miR-124-3p | Major depressive disorder | MNDR-E-MI-06130 |
| MNDR | hsa-miR-124-3p | Depression | MNDR-E-MI-06131 |
| MNDR | hsa-miR-124-3p | Breast cancer | MNDR-E-MI-06132 |
| MNDR | hsa-miR-124-3p | Cancer | MNDR-E-MI-06133 |
| MNDR | hsa-miR-124-3p | Thyroid cancer | MNDR-E-MI-06134 |
| MNDR | hsa-miR-124-3p | Pituitary neoplasms | MNDR-E-MI-06135 |
| MNDR | hsa-miR-124-3p | Pancreatic cancer | MNDR-E-MI-06136 |
| MNDR | hsa-miR-124-3p | Hepatitis C | MNDR-E-MI-06137 |
| MNDR | hsa-miR-124-3p | Melanoma | MNDR-E-MI-06138 |
| MNDR | hsa-miR-124-3p | Nephroblastoma | MNDR-E-MI-06139 |
| MNDR | hsa-miR-124-3p | Colon cancer | MNDR-E-MI-06140 |
| MNDR | hsa-miR-124-3p | Ischemic attack transient | MNDR-E-MI-06141 |
| MNDR | hsa-miR-124-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-06142 |
| MNDR | hsa-miR-124-3p | Familial ovarian cancer | MNDR-E-MI-06143 |
| MNDR | hsa-miR-124-3p | Acromegaly | MNDR-E-MI-06144 |
| MNDR | hsa-miR-124-3p | Kidney cancer | MNDR-E-MI-06145 |
| MNDR | hsa-miR-124-3p | Cerebellar disease | MNDR-E-MI-06146 |
| MNDR | hsa-miR-124-3p | Glioblastoma | MNDR-E-MI-06147 |
| MNDR | hsa-miR-124-3p | Astrocytoma | MNDR-E-MI-06148 |
| MNDR | hsa-miR-124-3p | Glioma | MNDR-E-MI-06149 |
| MNDR | hsa-miR-124-3p | Oligodendroglioma | MNDR-E-MI-06150 |
| MNDR | hsa-miR-124-3p | Teratocarcinoma | MNDR-E-MI-06151 |
| MNDR | hsa-miR-124-3p | Central nervous system disease | MNDR-E-MI-06152 |
| MNDR | hsa-miR-124-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-06153 |
| MNDR | hsa-miR-124-3p | Epilepsy temporal lobe | MNDR-E-MI-06154 |
| MNDR | hsa-miR-124-3p | Osteosarcoma | MNDR-E-MI-06155 |
| MNDR | hsa-miR-124-3p | Ewing sarcoma | MNDR-E-MI-06156 |
| MNDR | hsa-miR-124-3p | Pancreatic duct adenocarcinoma | MNDR-E-MI-06157 |
| MNDR | hsa-miR-124-3p | Meningioma | MNDR-E-MI-06158 |
| MNDR | hsa-miR-124-3p | Liver cancer | MNDR-E-MI-06159 |
| MNDR | hsa-miR-124-3p | Pituitary adenoma | MNDR-E-MI-06160 |
| MNDR | hsa-miR-124-3p | Carcinoma lung non-small-cell | MNDR-E-MI-06161 |
| MNDR | hsa-miR-124-3p | Lung adenocarcinoma | MNDR-E-MI-06162 |
| MNDR | hsa-miR-124-3p | Papillary thyroid carcinoma | MNDR-E-MI-06163 |
| MNDR | hsa-miR-124-3p | Cervical cancer | MNDR-E-MI-06164 |
| MNDR | hsa-miR-124-3p | Renal cell carcinoma | MNDR-E-MI-06165 |
| MNDR | hsa-miR-124-3p | Renal clear cell carcinoma | MNDR-E-MI-06166 |
| MNDR | hsa-miR-124-3p | Biliary tract cancer | MNDR-E-MI-06167 |
| MNDR | hsa-miR-124-3p | Neoplasms of the small intestine | MNDR-E-MI-06168 |
| MNDR | hsa-miR-124-3p | Cholangiocarcinoma | MNDR-E-MI-06169 |
| MNDR | hsa-miR-124-3p | Esophageal cancer | MNDR-E-MI-06170 |
| MNDR | hsa-miR-124-3p | Lung small cell carcinoma | MNDR-E-MI-06171 |
| MNDR | hsa-miR-124-3p | Encephalopathy bovine spongiform | MNDR-E-MI-06172 |
| MNDR | hsa-miR-124-3p | Uveal melanoma | MNDR-E-MI-06173 |
| MNDR | hsa-miR-124-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-06174 |
| MNDR | hsa-miR-124-3p | Bladder transitional cell carcinoma | MNDR-E-MI-06175 |
| MNDR | hsa-miR-124-3p | Progressive supranuclear palsy | MNDR-E-MI-06176 |
| MNDR | hsa-miR-124-3p | Hepatocellular carcinoma | MNDR-E-MI-06177 |
| MNDR | hsa-miR-124-3p | Familiar ovarian carcinoma | MNDR-E-MI-06178 |
| MNDR | hsa-miR-124-3p | B-cell lymphoma | MNDR-E-MI-06179 |
| MNDR | hsa-miR-124-3p | Retinoblastoma | MNDR-E-MI-06180 |
| MNDR | hsa-miR-124-3p | Neuroblastoma | MNDR-E-MI-06181 |
| MNDR | hsa-miR-124-3p | Barrett's adenocarcinoma | MNDR-E-MI-06182 |
| MNDR | hsa-miR-124-3p | Hodgkin lymphoma | MNDR-E-MI-06183 |
| MNDR | hsa-miR-124-3p | Tongue cancer | MNDR-E-MI-06184 |
| MNDR | hsa-miR-124-3p | Ritter's disease | MNDR-E-MI-06185 |
| MNDR | hsa-miR-124-3p | Acute myelogenous leukemia | MNDR-E-MI-06186 |
| MNDR | hsa-miR-124-3p | Colorectal cancer | MNDR-E-MI-06187 |
| MNDR | hsa-miR-124-3p | Nasopharyngeal carcinoma | MNDR-E-MI-06188 |
| MNDR | hsa-miR-124-3p | Type 2 diabetes mellitus | MNDR-E-MI-06189 |
| MNDR | hsa-miR-124-3p | Multiple myeloma | MNDR-E-MI-06190 |
| MNDR | hsa-miR-124-3p | Nasopharyngeal carcinoma | MNDR-E-MI-06191 |
| MNDR | hsa-miR-124-3p | Leukemia lymphoblastic acute | MNDR-E-MI-06192 |
| MNDR | hsa-miR-124-3p | Ovarian epithelial cancer | MNDR-E-MI-06193 |
| MNDR | hsa-miR-124-3p | Uterine cervical neoplasms | MNDR-E-MI-06194 |
| MNDR | hsa-miR-124-3p | Ependymoma | MNDR-E-MI-06195 |
| MNDR | hsa-miR-124-3p | Prostatic neoplasms | MNDR-E-MI-06196 |
| MNDR | hsa-miR-124-3p | Gait ataxia | MNDR-E-MI-06197 |
| MNDR | hsa-miR-124-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-06198 |
| MNDR | hsa-miR-124-3p | Stroke lacunar | MNDR-E-MI-06199 |
| MNDR | hsa-miR-124-3p | Barrett's carcinogenesis | MNDR-E-MI-06200 |
| MNDR | hsa-miR-124-3p | Breast cancer her3+ negative | MNDR-E-MI-06201 |
| MNDR | hsa-miR-124-3p | Cerebellar neurodegeneration | MNDR-E-MI-06202 |
| MNDR | hsa-miR-124-3p | Cholestatic liver injury | MNDR-E-MI-06203 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABHD4 | Homo sapiens | RR00026289 |
TOP